Никотиновая зависимость у больных шизофренией: клинико-патогенетический аспект и влияние на лечение

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Сперанская О.И., Качаева М.А., Трущелёв С.А. Никотиновая зависимость у больных шизофренией: клинико-патогенетический аспект и влияние на лечение // Российский психиатрический журнал. 2018. №4. С. 40-47.

Аннотация

В научном обзоре с целью обобщения результатов исследований о никотиновой зависимости рассмотрены данные о распространенности этого явления среди больных шизофренией, а также изучен клинико-патогенетический аспект и влияние на лечение. По результатам обзора установлена тесная связь частоты никотиновой зависимости и шизофрении. Такая ассоциация влияет на патогенетические звенья развития болезни и сильно воздействует на результативность лечения. Изучено 318 тематически связанных научных публикаций, в обзор включено 63.

Ключевые слова шизофрения; никотин; патогенез; зависимость; лечение

Литература

1. Jastrebov VS, Shevchenko LS, Ljubov EB, et al. Sovershenstvovanie metodiki provedenija stoimostnogo analiza i utochnenie jekonomicheskogo bremeni psihicheskih rasstrojstv v Rossii. Psihicheskoe zdorov'e. 2014;12(10):3-7. Russian. 2. Trushchelev SA. Global'noe bremja psihicheskih boleznej. Zdravoohranenie Rossijskoj Federacii. 2009;(4):33-39. Russian. 3. Golenkov AV. Tabakokurenie pri shizofrenii: chastnyj vopros ili global'naja problema?. Narkologija. 2010;9(11):57-64. Russian. 4. Gurovich IJa. Napravlenija sovershenstvovanija psihiatricheskoj pomoshhi. Social'naja i klinicheskaja psihiatrija. 2014;24(1):5–9. Russian. 5. Kachaeva MA, Shport SV, Trushchelev SA. [WHO strategic directions for the protection of mental health]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(6):10-23. Russian. 6. Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284:2606-10. 7. Kachaeva MA. [Woman and society: social-psychological, biological, and clinical aspects of preservation of health]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2017;(2):65-71. Russian. 8. McCreadie RG, Kelly C. Patients with schizophrenia who smoke: private disaster, public resource. Br J Psychiatry. 2000;176:109. 9. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328:1519. 10. Goff DC, Cather C, Evins AE, et al. Medical morbidity and mortality in schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005;66:183-194. 11. Widysanto A, Saadabadi A. Nicotine Addiction. Treasure Island (FL): StatPearls Publishing; 2018. PMID: 29763090 12. Evins E.A. Nicotine Dependence in Schizophrenia: Prevalence, Mechanisms, and Implications for Treatment. Psychiatric Times. 2008;25(3): Available at: http://www.psychiatrictimes.com 13. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease / A Report of the Surgeon General; U.S. Department of health and human services. Rockville (MD), 2010; 727 p. 14. Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology. 2011 Jun;60(7-8):1209-20. doi: 10.1016/j.neuropharm.2010.11.010. Epub 2010 Nov 22. 15. Jacobsen LK, D'Souza DC, Mencl WE, et al. Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry. 2004;55:850-858. 16. Speranskaya OI, Storozheva ZI, Ustinova MI. Kliniko-biologicheskie osobennosti tabachnoj zavisimosti u dlitel'no kurjashhih lic s zabolevanijami serdechno sosudistoj sistemy: taktika lechebno-profilakticheskih meroprijatij. Mezhdunarodnyj nauchno-issledovatel'skij zhurnal. 2018;(3):139-43. Russian. 17. Gudehithlu KP, Duchemin AM, Tejwani GA, Neff NH, Hadjiconstantinou M. Nicotine-induced changes of brain β-endorphin. Neuropeptides. 2012 Jun;46(3):125-31. doi: 10.1016/j.npep.2012.03.001. Epub 2012 Apr 4. 18. McLaughlin I. Nicotine Withdrawal. Curr Top Behav Neurosci. 2015; 24: 99–123. doi: 10.1007/978-3-319-13482-6_4; PMID: 25638335 19. Speranskaya OI, Storozheva ZI, Bochkarev VK, Kovaleva ME. Kliniko-geneticheskaja predikcija farmakorezistentnosti u lic s tabachnoj zavisimost'ju. Voprosy narkologii. 2017;(11): 21-31. Russian. 20. Durany N, Zöchling R, Boissl KW, et al. Human post-mortem striatal a4b2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett. 2000;287:109-12. 21. Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry. 1995;38:22-33. 22. Leonard S, Gault J, Hopkins J, et al. Association of promoter variants in the a7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry. 2002;59:1085-96. 23. Adler LE, Hoffer LD, Wiser A, Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry. 1993; 150:1856-61. 24. Koukouli F, Rooy M, Tziotis D, et al. Nicotine reverses hypofrontality in animal models of addiction and schizophrenia. Nature Medicine. Published online 23 January 2017. doi: 10.1038/nm.4274 25. Pahomova SA, Abrosimova JuS, Matrosova OS. Osobennosti nikotinovoj zavisimosti pri shizofrenii. Vestnik nevrologii, psihiatrii i nejrohirurgii. 2015;(4):3-8. Russian. 26. Lawrence NS, Ross TJ, Stein EA. Cognitive mechanisms of nicotine on visual attention. Neuron. 2002; 36:539-48. 27. Goff DC, Evins AE. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry. 1998;6:59-77. 28. Levin E, Icenogle L, Farzad A. Ketanserin attenuates nicotine-induced working memory improvement in rats. Pharmacol Biochem Behav. 2005;82:289-92. 29. McGehee D, Heath M, Gelber S, et al. Nicotine enhancement of fast excitatory synaptic transmission in the CNS by presynaptic receptors. Science. 1995;269:1692-6. 30. Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction. 1994;89:1419-23. 31. Willisms JM, Gandhi KK, et al. Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch. J Dual Diagn. 2008;(4):355-76. 32. Rezvani AH, Levin ED. Nicotine-antipsychotic drug interactions and attentional performance in female rats [published correction appears in Eur J Pharmacol. 2004;489:215]. Eur J Pharmacol. 2004;486:175-82. 33. Harris JG, Kongs S, Allensworth D, et al. Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology. 2004;29:1378-85. 34. Barr RS, Culhane MA, Jubelt LE, et al. The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology. 2008;33:480-90. 35. Smith RC, Singh A, Infante M, et al. Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology. 2002;27:479-97. 36. Myers CS, Robles O, Kakoyannis AN, et al. Nicotine improves delayed recognition in schizophrenic patients. Psychopharmacology (Berl). 2004;174:334-40. 37. Griffith JM, O'Neill JE, Petty F, et al. Nicotinic receptor desensitization and sensory gating deficits in schizophrenia. Biol Psychiatry. 1998;44:98-106. 38. Levin ED, Briggs SJ, Christopher NC, Rose JE. Persistence of chronic nicotine-induced cognitive facilitation. Behav Neural Biol. 1992;58:152-8. 39. Adler LE, Olincy A, Cawthra EM, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004;161: 1822-8. 40. Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord. 2002;1:149-62. 41. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995;37:550-2. 42. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999;46:125-9. 43. Addy NA, Pocivavsek A, Levin ED. Reversal of clozapine effects on working memory in rats with fimbria-fornix lesions. Neuropsychopharmacology. 2005;30:1121-7. 44. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835-42. 45. Alfimov PV, Oleneva EV, Mosolov SN. Prognosticheskie faktory terapevticheskoj jeffektivnosti klozapina pri shizofrenii. Sovremennaja terapija psihicheskih rasstrojstv. 2013;(2):21-9. Russian. 46. Speranskaya OI, Smirnov VK, Bogdanov KA. Pervichnaja i vtorichnaja terapevticheskaja rezistentnost' k nikotinzamestitel'noj terapii u lic s tabachnoj zavisimost'ju. Zhurnal nevrologii i psihiatrii im. C.C. Korsakova. 2013;113(9):59-62. Russian. 47. McEvoy JP, Freudenreich O, Levin ED, Rose JE. Haloperidol increases smoking in patients with schizophrenia. Psychopharmacology (Berl). 1995; 119:124-6. 48. Miller D, Kelly M, Perry P, Coryell W. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry. 1990;28:529-31. 49. Goff DC, Henderson DC, Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry. 1992;149:1189-94. 50. Levin ED, Wilson W, Rose JE, McEvoy J. Nicotine-haloperidol interactions and cognitive performance in schizophrenics. Neuropsychopharmacology. 1996;15:429-36. 51. Evins A, Cather C, Rigotti N, et al. Two-year follow up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004;65:307-311. 52. Williams JM, Ziedonis DM, Foulds J. A case series of nicotine nasal spray in the treatment of tobacco dependence among patients with schizophrenia. Psychiatr Serv. 2004;55:1064-6. 53. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934-42. 54. Hall SM, Humfleet GL, Reus VI, et al. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry. 2002;59: 930-6. 55. Hays JT, Hurt RD, Rigotti NA, et al. Sustained- release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med. 2001;135:423-33. 56. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380-6. 57. Saxon AJ, Baer JS, Davis TM, et al. Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies. Nicotine Tob Res. 2003;5:589-96. 58. Blondal T, Gudmundsson L, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow-up [published correction appears in BMJ. 1999;318: 764]. BMJ. 1999;318:285-8. 59. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med. 1995;24:41-7. 60. [Information and communication strategy for promoting the healthy way of life, countering alcohol and tobacco use, preventing and opposing the non-medical use of addictive drugs and psychotropic substances till the year 2020]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2018;(2):78-87. Russian. 61. Golenkov AV. Diagnostika i profilaktika tabachnoj zavisimosti u bol'nyh shizofreniej. Medicinskaja sestra. 2016;(3):7-11. Russian. 62. Mccreadie R. Potreblenie psihoaktivnyh veshhestv, alkogolja i kurenie tabaka licami, stradajushhimi shizofreniej: issledovanie tipa sluchaj-kontrol'. Voprosy narkologii. 2003;(5):73-4. Russian. 63. Barnes M, Lawford B R, Burton SS, et al. Schizophrenia and Smoking: what antipsychotic drugs are effective in quitting?. Austral And NZJ Psych. 2006;40(6):575-80.



DOI: http://dx.doi.org/10.24411/1560-957X-2018-1%25x

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM